February 22, 2012
Fitch, Even, Tabin & Flannery LLP welcomes you to a complimentary webinar, “Patent Reexaminations in Parallel with Litigation,” presented by Joseph E. Shipley. The webinar will take place on Wednesday, February 22, 2012, at 9:00 am PST / 10:00 am MST / 11:00 am CST / 12:00 noon EST.
Reexamination proceedings in the U.S. Patent and Trademark Office (USPTO) are increasingly used as an alternative or adjunct to litigating validity in the federal courts. As reexamination procedures grow in popularity, it is becoming more and more important for patent attorneys to understand the factors that should be considered in deciding whether to seek reexamination. Our February webinar will cover these factors in depth, addressing the following topics and more:
- Objectives: What can be achieved in reexamination and what cannot
- Current statistics on outcomes
- Associated risks
- Associated costs
- Time frames
- Reexamination options
- Alternatives to reexamination
We will also briefly discuss two new USPTO procedures that will become available on September 16, 2012--Post-Grant Review and Inter Partes Review--and will compare and contrast these with the current procedures. The webinar will conclude with an interactive question and answer session.
Our speaker will be Fitch Even partner Joseph E. Shipley. For over 25 years, Joe has assisted clients with global patent portfolio management, freedom-to-operate issues, complex litigation, and transactions. He has extensive experience in both U.S. and international work involving patent prosecution and post-issuance challenges in reexaminations and other proceedings. Joe’s practice focuses on first understanding clients’ business issues, then developing and executing creative IP strategies to address the clients’ needs in a highly efficient manner.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more